Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it
Page 10 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.
- Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection FractionStatus unknownNCT04475042Phase 2
- Empagliflozin and Cardiac Remodelling in People Without DiabetesCompletedNCT04461041Phase 4
- Semaglutide and Dapagliflozin in Diabetic Patients With Different PathophysiologyActive, not recruitingNCT04451837Phase 2
- Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic HyponatremiaCompletedNCT04447911Phase 4
- Pharmacokinetic Drug Interaction Between Teneligliptin and EmpagliflozinCompletedNCT04431141Phase 1
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and MechanismsCompletedNCT04393246Phase 2/3
- Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart FailureCompletedNCT04385589Phase 4
- Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlCompletedNCT04356742Phase 3
- Pharmacological Reduction of Right Ventricular EnlargementCompletedNCT04345796Phase 3
- Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male AdultsStatus unknownNCT04343547Phase 1
- Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac SurgeryStatus unknownNCT04340908Phase 4
- Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration TrialActive, not recruitingNCT04333823Phase 3
- Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery DiseaseTerminatedNCT04330079Phase 4
- Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical TrialStatus unknownNCT04304560Phase 2
- Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)CompletedNCT04304261Phase 3
- Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic AgentsStatus unknownNCT04287387Phase 4
- A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin AloneStatus unknownNCT04255238Phase 3
- REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs PopulationsWithdrawnNCT04243850Phase 4
- Phthalates Exposure in Type 2 Diabetic Patients and Diuretic TherapyStatus unknownNCT04242758Phase 4
- Renohemodynamic Effects of Combined empagliflOzin and LosARtanCompletedNCT04238702Phase 4
- Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult VolunteersCompletedNCT04237597Phase 1
- Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)TerminatedNCT04234867Phase 1
- Type 2 Diabetes Patients With Renal ImpairmentStatus unknownNCT04221399Phase 1
- A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )Status unknownNCT04221152Phase 3
- Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKDStatus unknownNCT04215445Phase 4
- Dapagliflozin Efficacy and Action in PCOSCompletedNCT04213677Phase 3
- Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 DiabetesStatus unknownNCT04203927Early Phase 1
- Short Term Effect of Empagliflozin in HypertensionCompletedNCT04203914Phase 4
- The Effects of SGLTi on Diabetic CardiomyopathyStatus unknownNCT04200586Phase 4
- Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes MellitusStatus unknownNCT04195243Phase 3
- Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 DiabetesCompletedNCT04193566Phase 4
- Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)CompletedNCT04183868Phase 4
- SGLT2 Inhibitors in Glomerular HyperfiltrationWithdrawnNCT04143581Phase 2
- Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory AnginaCompletedNCT04143321Phase 4
- Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 DeficiencyStatus unknownNCT04138251Phase 2
- Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With PrediabetesStatus unknownNCT04131582Phase 3
- Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes MellitusStatus unknownNCT04120623Phase 4
- Effect of Empagliflozin on Ventricular Repolarization.CompletedNCT04117763Phase 4
- Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor TreatmentCompletedNCT04080518Phase 4
- A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid TumorsStatus unknownNCT04073680Phase 1/2
- Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)CompletedNCT04064073Phase 1
- Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon SecretionCompletedNCT04061473Not applicable
- Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and AlbuminuriaStatus unknownNCT04061200Phase 4
- Dapagliflozin in Physical Exercise in Type 1 DiabetesCompletedNCT04049110Phase 3
- Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart FailureCompletedNCT04049045Phase 2
- Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 DiabetesCompletedNCT04035031Phase 3
- Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.CompletedNCT04027530Phase 4
- A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin ResistanceStatus unknownNCT04018365Phase 3
- Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes MellitusStatus unknownNCT04014192Phase 4
- Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes MellitusStatus unknownNCT04014023Phase 2
- Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)CompletedNCT04004793Phase 4
- SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 DiabetesCompletedNCT03982381Phase 4
- Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes PatientsCompletedNCT03982238Phase 4
- Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient SettingCompletedNCT03979352Phase 3
- Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.CompletedNCT03970044Phase 4
- Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.Status unknownNCT03961659Not applicable
- Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin TherapyCompletedNCT03959501Phase 4
- Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)TerminatedNCT03933956Phase 3
- SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney DiseaseCompletedNCT03919656Phase 4
- Antidiuretic Function Before and During Treatment With SGLT2 InhibitorsStatus unknownNCT03917758Not applicable
- Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in HumansStatus unknownNCT03912909Phase 4
- Sotagliflozin Multiple-dose Study in Healthy Chinese SubjectsCompletedNCT03909451Phase 1
- Triple Therapy in T1DMActive, not recruitingNCT03899402Phase 2/3
- The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of EmpagliflozinCompletedNCT03895229Phase 1
- Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 DiabetesStatus unknownNCT03887416Phase 4
- Effect of Empagliflozin on Body Composition and KetonesStatus unknownNCT03877406Phase 4
- Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment TrialCompletedNCT03871621Phase 4
- Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed ConditionStatus unknownNCT03849339Phase 1
- Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy AdultsStatus unknownNCT03849261Phase 1
- Approaches To Therapy Escalation In T2DWithdrawnNCT03813316Phase 4
- Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female SubjectsCompletedNCT03802487Phase 1
- Drug Interaction Study Between Dorzagliatin and EmpagliflozinCompletedNCT03790787Phase 1
- A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted ConditionsCompletedNCT03776227Phase 1
- Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.CompletedNCT03771781Not applicable
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male AdultsCompletedNCT03766724Phase 1
- Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without SulfonylureaTerminatedNCT03761134Phase 3
- Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and ExerciseTerminatedNCT03760965Phase 3
- Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes MellitusCompletedNCT03753087Phase 4
- The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed ConditionCompletedNCT03738449Phase 1
- Dapagliflozin Efficacy and Action in NASHCompletedNCT03723252Phase 3
- Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate OxidationCompletedNCT03721874Phase 4
- Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.CompletedNCT03714594Phase 2
- Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).CompletedNCT03713190Phase 2
- Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in ObesityStatus unknownNCT03710460Phase 4
- Dapagliflozin Effects on HypoglycemiaCompletedNCT03704818Phase 1
- Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial InfarctionStatus unknownNCT03658031Phase 3
- Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy AdultsStatus unknownNCT03646799Phase 1
- Antidiabetic Drugs for Steatotic Liver DiseaseCompletedNCT03646292Phase 4
- Efficacy and Safety of Empagliflozin in NODATTerminatedNCT03642184Phase 4
- Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.WithdrawnNCT03640221Phase 4
- The Effects of Empagliflozin on Arterial Wall CharacteristicsStatus unknownNCT03639545Phase 4
- Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal InsulinStatus unknownNCT03631134Phase 4
- Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/SaxagliptinTerminatedNCT03608358Phase 3
- Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in HypertensionStatus unknownNCT03592667Phase 4
- Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCIStatus unknownNCT03591991Not applicable
- Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic PatientsStatus unknownNCT03573102Phase 4
- Gemigliptin, Dapagliflozin, Empagliflozin DDI StudyStatus unknownNCT03565458Phase 1
- Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study ProtocolCompletedNCT03560375Phase 4
- Effect of Dapagliflozin on IAH in T1DMCompletedNCT03556033Phase 2
- EMPA Acute Heart FailureTerminatedNCT03554200Phase 2